2024

• Novis, E., Glover, A., Grady, J., Silvestri, A., Thavaneswaran, S., Lin, F., Ballinger, M., Thomas, D. (2024). Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program. Surgery. [More Information]
• Deng, F., Li, Y., Yang, B., Sang, R., Deng, W., Kansara, M., Lin, F., Thavaneswaran, S., Thomas, D., Goldys, E. (2024). Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing. Nature Communications, 15(1). [More Information]

2023

• Thavaneswaran, S., Kansara, M., Lin, F., Espinoza, D., Grady, J., Lee, C., Ballinger, M., Sebastian, L., Corpuz, T., Qiu, M., Bailey, C., Schmitz, U., Simes, R., et al (2023). A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. British Journal of Cancer, 129(3), 475-485. [More Information]
• Kansara, M., Bhardwaj, N., Thavaneswaran, S., Xu, C., Lee, J., Chang, L., Madison, R., Lin, F., Hsu, E., Patel, V., Simes, R., et al (2023). Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab. Molecular Oncology, 17(2), 298-311. [More Information]
• Zeverijn, L., Looze, E., Thavaneswaran, S., van Berge Henegouwen, J., Simes, R., Hoes, L., Sjoquist, K., van der Wijngaart, H., Sebastian, L., Geurts, B., Lee, C., Espinoza, D., Lin, F., et al (2023). Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. International Journal of Cancer, 153(7), 1413-1422. [More Information]

2021

• Lin, F., Thavaneswaran, S., Grady, J., Ballinger, M., Oakes, S., Desai, J., Lee, C., Simes, R., Thomas, D. (2021). Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. n p j Precision Oncology, 5(1), 58. [More Information]
• Siu, D., Tebbutt, N., Chantrill, L., Karapetis, C., Steer, C., Wilson, K., Espinoza, D., Bailey, L., Yip, S., Cuff, J., Pavlakis, N., Thavaneswaran, S., Shannon, J., Segelov, E., Price, T., Sjoquist, K., et al (2021). MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer, 21(1), 932. [More Information]
• Thavaneswaran, S., Ballinger, M., Butow, P., Meiser, B., Goldstein, D., Lin, F., Napier, C., Thomas, D., Best, M. (2021). The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey. Oncotarget, 12(21), 2169-2176. [More Information]

2019

• Thavaneswaran, S., Rath, E., Tucker, K., Joshua, A., Hess, D., Pinese, M., Ballinger, M., Thomas, D. (2019). Therapeutic implications of germline genetic findings in cancer. Nature Reviews Clinical Oncology, 16(6), 386-396. [More Information]

2018

• Shapiro, J., Thavaneswaran, S., Underhill, C., Robledo, K., Karapetis, C., Day, F., Nott, L., Jefford, M., Chantrill, L., Pavlakis, N., Khasraw, M., Simes, R., Gebski, V., et al (2018). Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 17(4), 313-319. [More Information]

2017

• Thavaneswaran, S., Kok, P., Price, T. (2017). Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 17(10), 965-979. [More Information]

2016

• Segelov, E., Waring, P., Desai, J., Wilson, C., Gebski, V., Thavaneswaran, S., Elez, E., Underhill, C., Pavlakis, N., Chantrill, L., Khasraw, M., et al (2016). ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 16(1), 1-8. [More Information]
• Thavaneswaran, S., Shapiro, J., Segelov, E. (2016). Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours? Translational Cancer Research, 5, S1214-S1221. [More Information]
• Thavaneswaran, S., Price, T. (2016). Optimal therapy for resectable rectal cancer. Expert Review of Anticancer Therapy, 16(3), 285-302. [More Information]
• Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Robledo, K., Gebski, V., Elez, E., Nott, L., Karapetis, C., Lunke, S., Pavlakis, N., Khasraw, M., Wilson, C., Simes, R., et al (2016). Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 34(19), 2258-2264. [More Information]
• Price, T., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D., Punt, C., Arnold, D., Karapetis, C., Tebbutt, N., Pavlakis, N., Gibbs, P., et al (2016). Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 16(5), 557-571. [More Information]

2013

• Peterson, T., Kimani, J., Wachihi, C., Bielawny, T., Mendoza, L., Thavaneswaran, S., Narayansingh, M., Kariri, T., Liang, B., Ball, T., et al (2013). HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort. Tissue Antigens: immune response genetics, 81(2), 93-107. [More Information]